BROMOCRIPTINE MESYLATE (bromocriptine mesylate) by Viatris (2) is clinical pharmacology bromocriptine mesylate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors. Approved for dysfunctions associated with hyperprolactinemia including amenorrhea with, without galactorrhea, infertility and 9 more indications. First approved in 2005.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Bromocriptine mesylate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor…
Worked on BROMOCRIPTINE MESYLATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.